About: Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice
Creator	Angel Perez, · Dagmara Pichardo, · Dioslaida Urquiza, · Falcon, Viviana Gillian Martinez-Donato, · Olivera, Santa
topic	covid:f1e8a368d45a13d539ecc6a5100ed498ace6aa6b#this
Source	PMC
abstract	The eradication of hepatitis C virus (HCV) infection is a public health priority. Despite the efficiency of treatment with direct-acting antivirals, the high cost of the therapy and the lack of accurate data about the HCV-infected population worldwide constitute important factors hampering this task. Hence, an affordable preventive vaccine is still necessary for reducing transmission and the future disease burden globally. In this work, chimeric proteins (EnvCNS3 and NS3EnvCo) encompassing conserved and immunogenic epitopes from the HCV core, E1, E2 and NS3 proteins were produced in Escherichia coli, and their immunogenicity was evaluated in BALB/c mice. The impact of recombinant HCV E2.680 protein and oligodeoxynucleotide 39M (ODN39M) on the immune response to chimeric proteins was also assessed. Immunization with chimeric proteins mixed with E2.680 enhanced the antibody and cellular response against HCV antigens and chimeric proteins. Interestingly, the combination of NS3EnvCo with E2.680 and ODN39M as adjuvant elicited a potent antibody response characterized by an increase in antibodies of the IgG2a subclass against E2.680, NS3 and chimeric proteins, suggesting the induction of a Th1-type response. Moreover, a cytotoxic T lymphocyte response and a broad response of IFN-γ-secreting cells against HCV antigens were induced with this formulation as well. This T cell response was able to protect vaccinated mice against challenge with a surrogate model based on HCV recombinant vaccinia virus. Overall, the vaccine candidate NS3EnvCo/E2.680/ODN39M might constitute an effective immunogen against HCV with potential for reducing the likelihood of viral persistence.
has issue date	2020-02-03(xsd:dateTime)
bibo:doi	10.1007/s00705-019-04464-x
bibo:pmid	32016547
has license	no-cc
sha1sum (hex)	f1e8a368d45a13d539ecc6a5100ed498ace6aa6b
schema:url	https://doi.org/10.1007/s00705-019-04464-x
resource representing a document's title	Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice
has PubMed Central identifier	PMC7224087
has PubMed identifier	32016547
schema:publication	Arch Virol
resource representing a document's body	covid:f1e8a368d45a13d539ecc6a5100ed498ace6aa6b#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/f1e8a368d45a13d539ecc6a5100ed498ace6aa6b
is schema:about of	named entity 'mice' named entity 'induction' named entity 'chimeric proteins' named entity 'disease burden' named entity 'cost' named entity 'factors' named entity 'population' named entity 'chimeric proteins' named entity 'potent' named entity 'type' named entity 'evaluated' named entity 'NS3' named entity 'antigens' named entity 'immunogenic' named entity 'assessed' named entity 'chimeric proteins' named entity 'recombinant' named entity 'vaccine' named entity 'Escherichia coli' named entity 'chimeric proteins' named entity 'antigens' named entity 'immunogen' named entity 'epitopes' named entity 'vaccinia virus' named entity 'antibodies' named entity 'mice' named entity 'recombinant' named entity 'NS3' named entity 'preventive vaccine' named entity 'cellular immune response' named entity 'Escherichia coli' named entity 'chimeric protein' named entity 'immunogenicity' named entity 'chimeric protein' named entity 'peptide' named entity 'adjuvant' named entity 'CpG' named entity 'epitope' named entity 'protein' named entity 'epitopes' named entity 'chimeric protein' named entity 'Promega' named entity 'Biotechnology' named entity 'enzyme' named entity 'cloning' named entity 'NS3' named entity 'HCV' named entity 'Havana' named entity 'NS3' named entity 'vaccinia' named entity 'HCV' named entity 'solubilized' named entity 'Sigma-Aldrich' named entity 'neutralizing antibody' named entity 'adjuvant' named entity 'Tris-HCl' named entity 'NS3' named entity 'IgG2a' named entity 'humoral' named entity 'HCV' named entity 'IFN-γ' named entity 'HCV' named entity 'protein' named entity 'dengue virus' named entity 'flow cytometry' named entity 'Mann-Whitney' named entity 'immunostimulatory' named entity 'CTL' named entity 'ovaries' named entity 'chimeric proteins' named entity 'NS4a' named entity 'Coomassie brilliant blue' named entity 'anthrax' named entity 'immunogenicity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software